Module 4: Acute Coronary Syndrome (ACS) and Cardiovascular Management

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/52

flashcard set

Earn XP

Description and Tags

Comprehensive practice flashcards covering pathophysiology, diagnostic criteria, biomarker analysis, evidence-based pharmacology, reperfusion pathways, and nursing care for Acute Coronary Syndrome (ACS).

53 Terms

1
New cards

Acute Coronary Syndrome (ACS)

A spectrum of conditions encompassing ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA), caused by unstable atheromatous plaque rupture or endothelial disruption with transient or permanent thrombotic occlusion of coronary arteries.

2
New cards
<p>Coronary Arteries (Heart Vascular Supply)</p>

Coronary Arteries (Heart Vascular Supply)

The arterial branches supplying oxygenated blood to the myocardium, predominantly comprising the Left Coronary Artery, Left Anterior Descending (LAD) artery, Left Circumflex artery, and Right Coronary Artery (RCA).

3
New cards

ST-Elevation Myocardial Infarction (STEMI)

An acute transmural myocardial necrosis caused by complete coronary artery occlusion, diagnosed by persistent (>20 minutes>20\,\text{minutes}) ST-segment elevation in ≥2\ge 2 contiguous leads or new-onset left bundle-branch block (LBBB).

4
New cards
<p>Non-ST-Elevation Acute Coronary Syndrome (NSTEACS)</p>

Non-ST-Elevation Acute Coronary Syndrome (NSTEACS)

An acute coronary syndrome entity encompassing NSTEMI and unstable angina, typically reflecting subendocardial ischaemia or partial vessel occlusion presenting with ST-segment depression, T-wave inversion, or normal ECGs.

5
New cards

Unstable Angina (UA)

Myocardial ischaemia at rest or with minimal exertion in the absence of acute cardiomyocyte necrosis, demonstrating normal serial cardiac biomarkers (troponin) and variable ECG changes.

6
New cards

Type 1 Myocardial Infarction

Spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more coronary arteries leading to decreased myocardial blood flow and myocyte necrosis.

7
New cards

Type 2 Myocardial Infarction

Myocardial necrosis resulting from a condition other than coronary artery disease that causes an imbalance between myocardial oxygen supply and demand (e.g., tachyarrhythmias, severe anaemia, respiratory failure, or severe hypotension/hypertension).

8
New cards

Hypertension

A chronic medical condition characterized by consistent elevation of systemic arterial blood pressure, clinically defined as a reading of 140/90 mmHg140/90\,\text{mmHg} or higher.

9
New cards

Mean Arterial Pressure (MAP)

The average pressure in the systemic arterial system throughout a complete cardiac cycle, representing tissue perfusion pressure.

10
New cards

Baroreceptors

Specialized stretch-sensitive mechanoreceptors located in the carotid sinus and aortic arch that become activated when arterial pressure or vascular wall stretch increases to regulate blood pressure.

11
New cards

Cardiac Output (CO)

The volume of blood pumped by the heart per minute, calculated using the formula: CO=HR×SV\text{CO} = \text{HR} \times \text{SV} (Heart Rate multiplied by Stroke Volume).

12
New cards

Aldosterone

A mineralocorticoid hormone stimulated by Angiotensin II that acts on the kidneys to promote sodium and water reabsorption, thereby expanding intravascular blood volume and elevating blood pressure.

13
New cards

Antidiuretic Hormone (ADH)

A posterior pituitary hormone that increases blood pressure primarily by increasing renal water reabsorption in the collecting ducts.

14
New cards

Modifiable Risk Factors for ACS

Controllable factors contributing to atherosclerosis and coronary thrombosis, including cigarette smoking, physical inactivity, dyslipidaemia (elevated LDL and triglycerides), obesity/high BMI (visceral abdominal fat), diabetes mellitus, hypertension, and chronic psychosocial stress.

15
New cards

Non-Modifiable Risk Factors for ACS

Inherent patient characteristics increasing cardiovascular risk, including advancing age (80%80\% of deaths occur in patients ≥65 years\ge 65\,\text{years}), male sex (earlier onset, though female risk rises post-menopause), family history in first-degree blood relatives (<55 years<55\,\text{years} in men, <65 years<65\,\text{years} in women), and genetic markers.

16
New cards

High-Sensitivity Cardiac Troponin T (hs-cTnT)

The preferred cardiac biomarker for detecting myocardial necrosis; it rises within 2–3 hours2\text{--}3\,\text{hours} of injury, peaks at 12–48 hours12\text{--}48\,\text{hours}, and remains elevated for 4–14 days4\text{--}14\,\text{days} (normal reference range: 0–14 ng/L0\text{--}14\,\text{ng/L}).

17
New cards

Creatine Kinase-MB (CK-MB)

A cardiac isoenzyme that elevates within 4–6 hours4\text{--}6\,\text{hours} of myocardial necrosis, peaks at approximately 24 hours24\,\text{hours}, and returns to baseline within 48–72 hours48\text{--}72\,\text{hours}; primarily useful for detecting early reinfarction.

18
New cards
<p>Myocardial Infarction Investigation Findings</p>

Myocardial Infarction Investigation Findings

A sequential pathophysiological cascade where tissue necrosis triggers inflammation (↑CRP\uparrow\text{CRP}, ↑WBC\uparrow\text{WBC}), myocyte cell membrane disruption releases intracellular enzymes (troponins, CK-MB), and ischaemia disrupts electrical conduction causing ST deviations and pathological Q waves.

19
New cards

Pathological Q Wave

An ECG waveform deflection greater than 2 small boxes (>0.04 seconds>0.04\,\text{seconds} in duration or greater than 25%25\% of R-wave amplitude) that signifies transmural myocardial necrosis or established scar.

20
New cards

T-Wave Tombstoning

An early, hyperacute ECG manifestation characterized by tall, peaked, symmetric T waves resulting from cellular hypoxia and localized potassium shifts during acute myocardial ischaemia.

21
New cards

Transmural Ischaemia

Ischaemia spanning the full thickness of the myocardial wall from endocardium to epicardium, characteristically causing ST-segment elevation on surface ECG leads.

22
New cards

Subendocardial Ischaemia

Ischaemic injury confined to the inner layer of the myocardium where tissue pressure is highest and perfusion lowest, typically manifesting on an ECG as ST-segment depression or T-wave inversion.

23
New cards
<p>ECG Myocardial Damage Localization Chart</p>

ECG Myocardial Damage Localization Chart

A diagnostic reference matching affected ventricular walls to ECG leads and coronary arteries: Anterior (V2–V4\text{V}_2\text{--}\text{V}_4, LAD), Anterolateral (I, aVL\text{aV}_\text{L}, V3–V6\text{V}_3\text{--}\text{V}_6, LAD/Circumflex), Septal (V1–V2\text{V}_1\text{--}\text{V}_2, LAD), Inferior (II, III, aVF\text{aV}_\text{F}, RCA), Lateral (I, aVL\text{aV}_\text{L}, V5–V6\text{V}_5\text{--}\text{V}_6, Circumflex), Posterior (V8–V9\text{V}_8\text{--}\text{V}_9, RCA/Circumflex), and Right Ventricular (V4R–V6R\text{V}_{4\text{R}}\text{--}\text{V}_{6\text{R}}, RCA).

24
New cards

Right Ventricular Infarction Signs

Clinical presentation resulting from backward right ventricular failure, characterized by jugular venous distension, hepatomegaly, systemic hypotension, and clear lung fields (dry chest).

25
New cards

Left Ventricular Infarction Signs

Clinical manifestations resulting from backward left ventricular failure, characterized by elevated pulmonary capillary wedge pressure, pulmonary oedema, dyspnoea, tachypnoea, hypoxia, and bilateral inspiratory crackles.

26
New cards

Diaphoresis in AMI

Profuse cold sweating without fever occurring during acute myocardial infarction due to intense activation of the sympathetic nervous system (SNS), considered an ominous red flag for STEMI.

27
New cards

MOAN Acronym

A traditional clinical mnemonic outlining initial pharmacological interventions for acute myocardial infarction: Morphine, Oxygen (only if SaO2<94%\text{SaO}_2 < 94\%), Aspirin (300 mg300\,\text{mg} oral loading dose), and Nitrates (sublingual or IV GTN).

28
New cards

Aspirin (in ACS)

An antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), blocking thromboxane A2\text{A}_2 synthesis; administered immediately as a 300 mg300\,\text{mg} chewed or dissolved loading dose (reducing 30-day mortality by 20%20\%), followed by 100–150 mg/day100\text{--}150\,\text{mg/day} indefinitely.

29
New cards

Glyceryl Trinitrate (GTN)

A nitrate vasodilator converted to nitric oxide (NO) that dilates systemic veins to reduce ventricular preload and wall stress, and dilates coronary arteries to enhance myocardial blood supply (0.3–0.6 mg0.3\text{--}0.6\,\text{mg} sublingual tablet or 0.4–0.8 mg0.4\text{--}0.8\,\text{mg} spray every 5 minutes5\,\text{minutes}, max 3 doses).

30
New cards

Morphine (in ACS)

An opioid analgesic administered at 2–2.5 mg2\text{--}2.5\,\text{mg} IV increments for persistent ischaemic chest pain that provides analgesia, anxiolysis, reduces sympathetic drive, and causes venodilation to decrease ventricular preload and myocardial oxygen demand.

31
New cards
<p>Percutaneous Coronary Intervention (PCI)</p>

Percutaneous Coronary Intervention (PCI)

A catheter-based coronary reperfusion technique using balloon angioplasty and bare-metal or drug-eluting stent deployment to mechanically restore lumen patency in an occluded culprit artery.

32
New cards

Primary PCI Timing Benchmarks

The preferred reperfusion therapy for STEMI if it can be performed within 90 minutes90\,\text{minutes} of First Medical Contact (FMC) or Door-to-Balloon (DTB) time <60 minutes<60\,\text{minutes}; superior to fibrinolysis in reducing mortality, recurrent infarction, and stroke.

33
New cards
<p>STEMI Reperfusion Strategy Pathways</p>

STEMI Reperfusion Strategy Pathways

An evidence-based decision tree dictating immediate primary PCI if door-in to door-out (DI-DO) and transfer to a PCI centre enables FMC-to-balloon time <90 minutes<90\,\text{minutes}; otherwise, immediate fibrinolytic therapy within 30 minutes30\,\text{minutes} door-to-needle (DTN) time is indicated.

34
New cards
<p>Tenecteplase (Metalyse)</p>

Tenecteplase (Metalyse)

A recombinant fibrin-specific tissue plasminogen activator (tPA) administered as a weight-tiered single IV bolus over 10 seconds: <60 kg=30 mg<60\,\text{kg} = 30\,\text{mg} (6 mL6\,\text{mL}); 60–<70 kg=35 mg60\text{--}<70\,\text{kg} = 35\,\text{mg} (7 mL7\,\text{mL}); 70–<80 kg=40 mg70\text{--}<80\,\text{kg} = 40\,\text{mg} (8 mL8\,\text{mL}); 80–<90 kg=45 mg80\text{--}<90\,\text{kg} = 45\,\text{mg} (9 mL9\,\text{mL}); ≥90 kg=50 mg\ge 90\,\text{kg} = 50\,\text{mg} (10 mL10\,\text{mL}). Doses are halved in patients aged ≥75 years\ge 75\,\text{years}.

35
New cards

Absolute Contraindications to Fibrinolysis

Clinical factors precluding fibrinolytic administration due to catastrophic bleeding risks: prior intracranial haemorrhage at any time, ischaemic stroke within 6 months, known central nervous system neoplasm/vascular malformation, major surgery/parenchymal biopsy/significant trauma within 2 months, active internal bleeding or haemorrhagic diathesis, and suspected aortic dissection.

36
New cards

Rescue Percutaneous Coronary Intervention

Emergency mechanical coronary reperfusion performed following failed fibrinolytic therapy, defined objectively by ≤50%\le 50\% ST-segment resolution on a 12-lead ECG at 60–90 minutes60\text{--}90\,\text{minutes} post-fibrinolysis or persistent haemodynamic instability.

37
New cards
<p>Coronary Artery Bypass Graft (CABG)</p>

Coronary Artery Bypass Graft (CABG)

A surgical revascularisation procedure utilizing harvested venous or arterial conduits to bypass coronary stenoses; recognized as the preferred revascularisation strategy over PCI in patients with diabetes mellitus and complex multi-vessel disease.

38
New cards

Post-Femoral Access PCI Nursing Orders

Specific vascular access protocols to prevent femoral pseudoaneurysm and haematoma: maintain strict supine bedrest (lay flat) for 4 hours4\,\text{hours}, sit at 30∘30^\circ for 6 hours6\,\text{hours}, perform lower-limb neurovascular observations hourly for 4 hours4\,\text{hours} then 4-hourly for 24 hours24\,\text{hours}, and inspect puncture site every 15 minutes15\,\text{minutes} for 1 hour, hourly for 4 hours4\,\text{hours}, then 4-hourly for 24 hours24\,\text{hours}.

39
New cards

Dual Antiplatelet Therapy (DAPT)

The combination of aspirin (100–150 mg/day100\text{--}150\,\text{mg/day}) and a potent P2Y12\text{P2Y}_{12} receptor inhibitor (ticagrelor 90 mg90\,\text{mg} BD, prasugrel 10 mg10\,\text{mg} daily, or clopidogrel 75 mg75\,\text{mg} daily) prescribed for 12 months after ACS to prevent stent thrombosis and secondary ischaemic events.

40
New cards

Ticagrelor

An oral, direct-acting, reversibly-binding P2Y12\text{P2Y}_{12} platelet receptor antagonist administered as a 180 mg180\,\text{mg} loading dose followed by 90 mg90\,\text{mg} twice daily; preferred over clopidogrel across all ACS presentations regardless of revascularisation strategy.

41
New cards

Prasugrel

A potent thienopyridine P2Y12\text{P2Y}_{12} inhibitor administered as a 60 mg60\,\text{mg} loading dose and 10 mg10\,\text{mg} daily maintenance for ACS patients undergoing PCI; contraindicated in patients with prior stroke/TIA, age ≥75 years\ge 75\,\text{years}, or body weight <60 kg<60\,\text{kg}.

42
New cards

Glycoprotein IIb/IIIa Inhibitors

Intravenous antiplatelet agents (e.g., abciximab, tirofiban, eptifibatide) that block the final common pathway of platelet aggregation by preventing fibrinogen cross-linking; indicated in combination with heparin during PCI in high-risk patients or for acute thrombotic complications.

43
New cards

Bivalirudin

A parenteral direct thrombin inhibitor (0.75 mg/kg0.75\,\text{mg/kg} IV bolus followed by 1.75 mg/kg/hr1.75\,\text{mg/kg/hr} infusion) utilized as an alternative to heparin plus GP IIb/IIIa inhibitors during PCI in patients with high baseline bleeding risk.

44
New cards

TIMI Risk Score for NSTEACS

A 7-point clinical risk stratification score (incorporating age ≥65\ge 65, ≥3\ge 3 CAD risk factors, known CAD >50%>50\%, aspirin use in past 7 days, ≥2\ge 2 angina episodes in 24 hours, ST deviation ≥0.5 mm\ge 0.5\,\text{mm}, and elevated biomarkers) predicting 14-day MACE risk.

45
New cards

GRACE Risk Score

A validated prognostic model (scoring 2 to 306) utilizing age, heart rate, systolic blood pressure, creatinine, Killip class, cardiac arrest at admission, ST deviation, and elevated enzymes to predict in-hospital and 6-month all-cause mortality in ACS.

46
New cards

CRUSADE Bleeding Score

A validated clinical score ranging from 0 to 96 points that quantifies the baseline probability of in-hospital major bleeding in NSTEACS to guide safe invasive and antithrombotic management.

47
New cards

ADAPT Accelerated Diagnostic Protocol

A 2-hour assessment protocol for emergency chest pain that identifies low-risk patients suitable for early discharge based on negative sensitive/highly-sensitive troponin at 0 and 2 hours, a TIMI score of 0 (or 0–1 in modified ADAPT), and normal serial ECGs.

48
New cards

Sgarbossa Criteria

ECG diagnostic rules for identifying acute myocardial infarction in the presence of Left Bundle Branch Block (LBBB): ST elevation ≥1 mm\ge 1\,\text{mm} concordant with QRS (5 points), ST depression ≥1 mm\ge 1\,\text{mm} in leads V1–V3\text{V}_1\text{--}\text{V}_3 (3 points), and ST elevation ≥5 mm\ge 5\,\text{mm} discordant with QRS (2 points); a score ≥3\ge 3 yields 98%98\% specificity for MI.

49
New cards

Serum Potassium Target in AMI

Maintaining serum potassium concentrations tightly around 4.0 mmol/L4.0\,\text{mmol/L} (normal reference range: 3.5–5.2 mmol/L3.5\text{--}5.2\,\text{mmol/L}) to stabilize cardiac myocyte resting membrane potentials and minimize ventricular tachyarrhythmias.

50
New cards
<p>Clinical Handover Standard Key Principles (NSW Health)</p>

Clinical Handover Standard Key Principles (NSW Health)

A standardized clinical communication framework encompassing six foundational principles: Leadership, Valuing Handover, Handover Participants, Handover Time, Handover Place (face-to-face at the bedside), and Handover Process utilizing structured communication tools like ISBAR.

51
New cards

ISBAR Communication Framework

A structured communication mnemonic utilized during clinical handover to ensure patient safety: Introduction (identify self, role, patient), Situation (immediate status/concern), Background (medical history, presentation), Assessment (current vital signs, clinical findings), and Recommendation (required actions, plan, timeframes).

52
New cards

Interactive ECG Online Video Series

A suite of three interactive multimedia modules ('The Heart in 3D', 'Electrical impulse', and 'Contraction') accessed with the password 'ECG' to reinforce foundational cardiac electrophysiology, depolarization waveforms, and chamber contraction mechanics.

53
New cards

Cardiac Rehabilitation

A comprehensive secondary prevention service comprising structured exercise training, lifestyle risk-factor counseling (smoking cessation, diet), and education that reduces 12-month cardiovascular mortality and hospital admissions post-ACS.